Ionis Pharmaceuticals (IONS) EBIAT: 2009-2025
Historic EBIAT for Ionis Pharmaceuticals (IONS) over the last 17 years, with Sep 2025 value amounting to -$128.6 million.
- Ionis Pharmaceuticals' EBIAT rose 8.45% to -$128.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$256.3 million, marking a year-over-year increase of 28.56%. This contributed to the annual value of -$453.9 million for FY2024, which is 23.92% down from last year.
- Ionis Pharmaceuticals' EBIAT amounted to -$128.6 million in Q3 2025, which was down 204.09% from $123.6 million recorded in Q2 2025.
- In the past 5 years, Ionis Pharmaceuticals' EBIAT ranged from a high of $224.6 million in Q4 2021 and a low of -$147.4 million during Q3 2023.
- Its 3-year average for EBIAT is -$88.4 million, with a median of -$124.3 million in 2023.
- In the last 5 years, Ionis Pharmaceuticals' EBIAT slumped by 1,026.51% in 2024 and then skyrocketed by 286.45% in 2025.
- Over the past 5 years, Ionis Pharmaceuticals' EBIAT (Quarterly) stood at $224.6 million in 2021, then tumbled by 123.34% to -$52.4 million in 2022, then spiked by 82.33% to -$9.3 million in 2023, then plummeted by 1,026.51% to -$104.3 million in 2024, then increased by 8.45% to -$128.6 million in 2025.
- Its EBIAT was -$128.6 million in Q3 2025, compared to $123.6 million in Q2 2025 and -$146.9 million in Q1 2025.